CA3212308A1 - Procedes et dispositifs de photobiomodulation - Google Patents
Procedes et dispositifs de photobiomodulation Download PDFInfo
- Publication number
- CA3212308A1 CA3212308A1 CA3212308A CA3212308A CA3212308A1 CA 3212308 A1 CA3212308 A1 CA 3212308A1 CA 3212308 A CA3212308 A CA 3212308A CA 3212308 A CA3212308 A CA 3212308A CA 3212308 A1 CA3212308 A1 CA 3212308A1
- Authority
- CA
- Canada
- Prior art keywords
- patient
- light
- head mounted
- data
- eeg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 147
- 210000004556 brain Anatomy 0.000 claims abstract description 77
- 238000005286 illumination Methods 0.000 claims abstract description 41
- 230000000926 neurological effect Effects 0.000 claims abstract description 14
- 208000029560 autism spectrum disease Diseases 0.000 claims description 80
- 210000003128 head Anatomy 0.000 claims description 75
- 230000001225 therapeutic effect Effects 0.000 claims description 75
- 238000002560 therapeutic procedure Methods 0.000 claims description 47
- 238000004891 communication Methods 0.000 claims description 45
- 206010003805 Autism Diseases 0.000 claims description 44
- 208000020706 Autistic disease Diseases 0.000 claims description 44
- 230000015654 memory Effects 0.000 claims description 39
- 230000006872 improvement Effects 0.000 claims description 30
- 230000008569 process Effects 0.000 claims description 30
- 208000024891 symptom Diseases 0.000 claims description 28
- 238000010801 machine learning Methods 0.000 claims description 27
- 230000003287 optical effect Effects 0.000 claims description 26
- 208000019901 Anxiety disease Diseases 0.000 claims description 20
- 230000036506 anxiety Effects 0.000 claims description 20
- 230000006870 function Effects 0.000 claims description 20
- 230000000638 stimulation Effects 0.000 claims description 20
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 19
- 230000009467 reduction Effects 0.000 claims description 19
- 230000004044 response Effects 0.000 claims description 18
- 230000007423 decrease Effects 0.000 claims description 17
- 210000000214 mouth Anatomy 0.000 claims description 15
- 210000005013 brain tissue Anatomy 0.000 claims description 14
- 238000013528 artificial neural network Methods 0.000 claims description 12
- 230000005540 biological transmission Effects 0.000 claims description 12
- 238000013479 data entry Methods 0.000 claims description 12
- 230000002829 reductive effect Effects 0.000 claims description 12
- 238000003780 insertion Methods 0.000 claims description 11
- 230000037431 insertion Effects 0.000 claims description 11
- 210000004204 blood vessel Anatomy 0.000 claims description 9
- 238000009826 distribution Methods 0.000 claims description 9
- 238000007726 management method Methods 0.000 claims description 8
- 238000011287 therapeutic dose Methods 0.000 claims description 8
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims description 7
- 210000000869 occipital lobe Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 210000002442 prefrontal cortex Anatomy 0.000 claims description 6
- 230000000306 recurrent effect Effects 0.000 claims description 5
- 238000012384 transportation and delivery Methods 0.000 claims description 5
- 230000002792 vascular Effects 0.000 claims description 5
- 238000013527 convolutional neural network Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 210000003478 temporal lobe Anatomy 0.000 claims description 4
- 206010019233 Headaches Diseases 0.000 claims description 3
- 230000007177 brain activity Effects 0.000 claims description 3
- 231100000869 headache Toxicity 0.000 claims description 3
- 230000006461 physiological response Effects 0.000 claims 2
- 230000003068 static effect Effects 0.000 claims 2
- 238000013523 data management Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 100
- 230000008449 language Effects 0.000 description 58
- 230000000694 effects Effects 0.000 description 37
- 238000004458 analytical method Methods 0.000 description 33
- 230000004907 flux Effects 0.000 description 28
- 238000005516 engineering process Methods 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 21
- 238000011160 research Methods 0.000 description 16
- 241000282472 Canis lupus familiaris Species 0.000 description 14
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 14
- 230000008859 change Effects 0.000 description 14
- 239000000902 placebo Substances 0.000 description 14
- 229940068196 placebo Drugs 0.000 description 14
- 238000010586 diagram Methods 0.000 description 12
- 230000007958 sleep Effects 0.000 description 12
- 206010016845 Foetal alcohol syndrome Diseases 0.000 description 11
- 208000025698 brain inflammatory disease Diseases 0.000 description 11
- 208000026934 fetal alcohol spectrum disease Diseases 0.000 description 11
- 201000007794 fetal alcohol syndrome Diseases 0.000 description 11
- 230000002407 ATP formation Effects 0.000 description 10
- 206010014599 encephalitis Diseases 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 238000012545 processing Methods 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 230000000007 visual effect Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 210000003470 mitochondria Anatomy 0.000 description 8
- 230000002123 temporal effect Effects 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 230000006399 behavior Effects 0.000 description 7
- 230000006735 deficit Effects 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 208000030886 Traumatic Brain injury Diseases 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 210000001652 frontal lobe Anatomy 0.000 description 6
- 230000001926 lymphatic effect Effects 0.000 description 6
- 230000004043 responsiveness Effects 0.000 description 6
- 230000009529 traumatic brain injury Effects 0.000 description 6
- 230000003442 weekly effect Effects 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 208000013404 behavioral symptom Diseases 0.000 description 5
- 230000001149 cognitive effect Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000002483 medication Methods 0.000 description 5
- 230000010355 oscillation Effects 0.000 description 5
- 230000010627 oxidative phosphorylation Effects 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 101100151946 Caenorhabditis elegans sars-1 gene Proteins 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 238000012706 support-vector machine Methods 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 206010062519 Poor quality sleep Diseases 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 210000001638 cerebellum Anatomy 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000013135 deep learning Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000001787 epileptiform Effects 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000000366 juvenile effect Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000006724 microglial activation Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000001123 neurodevelopmental effect Effects 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 230000003989 repetitive behavior Effects 0.000 description 3
- 208000013406 repetitive behavior Diseases 0.000 description 3
- 230000001755 vocal effect Effects 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 108050008072 Cytochrome c oxidase subunit IV Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000007476 Maximum Likelihood Methods 0.000 description 2
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 206010060860 Neurological symptom Diseases 0.000 description 2
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000007621 cluster analysis Methods 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000000205 computational method Methods 0.000 description 2
- 210000000877 corpus callosum Anatomy 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000003116 impacting effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 208000012268 mitochondrial disease Diseases 0.000 description 2
- 230000004065 mitochondrial dysfunction Effects 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000004766 neurogenesis Effects 0.000 description 2
- 230000004007 neuromodulation Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000012014 optical coherence tomography Methods 0.000 description 2
- 210000001152 parietal lobe Anatomy 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- 238000001126 phototherapy Methods 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- FEHAMBYTUPDFJE-UHFFFAOYSA-N 8-(benzylsulfanylmethyl)-1,3-dimethyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(C)C(=O)N(C)C=2N=C1CSCC1=CC=CC=C1 FEHAMBYTUPDFJE-UHFFFAOYSA-N 0.000 description 1
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000599985 Beijerinckia mobilis Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 1
- 101100269568 Danio rerio aldocb gene Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 101000643374 Homo sapiens Serrate RNA effector molecule homolog Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 208000033712 Self injurious behaviour Diseases 0.000 description 1
- 102100035712 Serrate RNA effector molecule homolog Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 101150057384 aldoc gene Proteins 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000003926 auditory cortex Anatomy 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000009225 cognitive behavioral therapy Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000037410 cognitive enhancement Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000000537 electroencephalography Methods 0.000 description 1
- 238000005430 electron energy loss spectroscopy Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000006397 emotional response Effects 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000005669 field effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006261 foam material Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000008140 language development Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003692 lymphatic flow Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 description 1
- 230000006676 mitochondrial damage Effects 0.000 description 1
- 230000006686 mitochondrial oxygen consumption Effects 0.000 description 1
- 238000010295 mobile communication Methods 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 238000000051 music therapy Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000001320 near-infrared absorption spectroscopy Methods 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000005693 optoelectronics Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000013439 planning Methods 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005594 polymer fiber Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000008667 sleep stage Effects 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 108020001568 subdomains Proteins 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0622—Optical stimulation for exciting neural tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/369—Electroencephalography [EEG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6802—Sensor mounted on worn items
- A61B5/6803—Head-worn items, e.g. helmets, masks, headphones or goggles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
- A61N2005/0606—Mouth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0626—Monitoring, verifying, controlling systems and methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
- A61N2005/0645—Applicators worn by the patient
- A61N2005/0647—Applicators worn by the patient the applicator adapted to be worn on the head
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Surgery (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
L'invention concerne des systèmes et des procédés pour le traitement d'états neurologiques dans lesquels un éclairage transcrânien utilisant des longueurs d'onde infrarouge, proche infrarouge et/ou rouge est appliqué dans le cerveau d'un patient à l'aide d'un dispositif portatif pouvant être porté sur la tête. L'invention concerne également des systèmes et des procédés pour appliquer une lumière à des tissus de patient en vue d'une photobiomodulation, en particulier à travers la bouche du patient.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162484P | 2021-03-17 | 2021-03-17 | |
| US63/162,484 | 2021-03-17 | ||
| US202163250703P | 2021-09-30 | 2021-09-30 | |
| US63/250,703 | 2021-09-30 | ||
| US202163272823P | 2021-10-28 | 2021-10-28 | |
| US63/272,823 | 2021-10-28 | ||
| US202263303384P | 2022-01-26 | 2022-01-26 | |
| US63/303,384 | 2022-01-26 | ||
| PCT/US2022/020770 WO2022197937A1 (fr) | 2021-03-17 | 2022-03-17 | Procédés et dispositifs de photobiomodulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3212308A1 true CA3212308A1 (fr) | 2022-09-22 |
Family
ID=81325048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3212308A Pending CA3212308A1 (fr) | 2021-03-17 | 2022-03-17 | Procedes et dispositifs de photobiomodulation |
Country Status (2)
| Country | Link |
|---|---|
| CA (1) | CA3212308A1 (fr) |
| WO (1) | WO2022197937A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4045140A1 (fr) | 2019-10-15 | 2022-08-24 | Jelikalite LLC | Dispositif de luminothérapie porté sur la tête |
| US11944840B2 (en) | 2021-04-08 | 2024-04-02 | Niraxx Light Therapeutics, Inc. | Photobiomodulation therapy garment, methods and uses |
| CA3216389A1 (fr) | 2021-04-08 | 2022-10-13 | Niraxx, Inc. | Vetement pour therapie par photobiomodulation, procedes et utilisations |
| US20240395388A1 (en) * | 2022-07-30 | 2024-11-28 | Reversal Solutions, Inc. | Ai-augmented photobiomodulation wellness system with a community of users |
| WO2024097374A2 (fr) * | 2022-11-02 | 2024-05-10 | Jelikalite Llc | Procédés et dispositifs de photobiomodulation |
| WO2024119165A2 (fr) * | 2022-12-02 | 2024-06-06 | Jelikalite Llc | Procédés et dispositifs de photobiomodulation |
| WO2025117795A2 (fr) * | 2023-12-01 | 2025-06-05 | Jelikalite Llc | Procédés et dispositifs de photobiomodulation |
| CN120079046A (zh) * | 2025-04-25 | 2025-06-03 | 西安交通大学医学院第一附属医院 | 一种面向临床应用的功能近红外光经颅多模态心理干预系统（tfNIRS-MPIS） |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8192473B2 (en) * | 2008-09-19 | 2012-06-05 | Apira Science, Inc. | Phototherapy apparatus for hair, scalp and skin treatment |
| US20130178731A1 (en) | 2010-08-13 | 2013-07-11 | Children's Medical Center Corporation | Methods and apparatus for risk assessment of developmental disorders during early cognitive development |
| EP3389767A1 (fr) * | 2015-12-15 | 2018-10-24 | Regents of the University of Minnesota | Systèmes et méthodes de traitement non invasif des céphalées |
| JP7025734B2 (ja) * | 2016-08-05 | 2022-02-25 | 有限会社ナガサキ・メソッド | 頭部光刺激装置およびプログラム |
| KR102612531B1 (ko) * | 2016-11-17 | 2023-12-12 | 코그니토 쎄라퓨틱스, 인코포레이티드 | 인지 기능 개선을 위한 시스템 |
| JP2020534042A (ja) * | 2017-09-18 | 2020-11-26 | リム ルー | フォトバイオモジュレーションを用いた自動個別化脳調整のシステムおよび方法 |
| US11358000B2 (en) * | 2019-01-17 | 2022-06-14 | Jack Tajkef | Pineal gland stimulator and regulator |
| EP4045140A1 (fr) * | 2019-10-15 | 2022-08-24 | Jelikalite LLC | Dispositif de luminothérapie porté sur la tête |
-
2022
- 2022-03-17 CA CA3212308A patent/CA3212308A1/fr active Pending
- 2022-03-17 WO PCT/US2022/020770 patent/WO2022197937A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022197937A1 (fr) | 2022-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11986667B2 (en) | Methods and devices for photobiomodulation | |
| US12290701B2 (en) | Head wearable light therapy device | |
| CA3212308A1 (fr) | Procedes et dispositifs de photobiomodulation | |
| US20230092770A1 (en) | Methods and devices for photobiomodulation | |
| CN110522983B (zh) | 基于人工智能的脑刺激系统、方法、设备和存储介质 | |
| US20240042198A1 (en) | Multifunctional closed loop neuro feedback stimulating device and methods thereof | |
| US11517743B2 (en) | Devices and methods for delivering mechanical stimulation to nerve, mechanoreceptor, and cell targets | |
| JP6605422B2 (ja) | ヒトの痛覚の測定の装置及び方法 | |
| JP6948550B2 (ja) | 記憶の固定を強化するための方法及び装置 | |
| Sitaram et al. | Hemodynamic brain–computer interfaces for communication and rehabilitation | |
| US20230233858A1 (en) | Method and device to enhance waste clearance in the brain | |
| US20180296793A1 (en) | Methods and Systems For Reducing Sound Sensitivities and Improving Auditory Processing, Behavioral State Regulation and Social Engagement Behaviors | |
| US12290383B2 (en) | Integrated artificial intelligence based system for monitoring and remediating withdrawal symptoms | |
| US20250262454A1 (en) | Methods and devices for photobiomodulation | |
| US20250288823A1 (en) | Methods and devices for photobiomodulation | |
| WO2024097374A2 (fr) | Procédés et dispositifs de photobiomodulation | |
| WO2025117795A2 (fr) | Procédés et dispositifs de photobiomodulation | |
| WO2024119165A2 (fr) | Procédés et dispositifs de photobiomodulation | |
| JP2025186320A (ja) | 頭部ウェアラブル光療法デバイス | |
| US20250387081A1 (en) | Integrated artificial intelligence based system for monitoring and remediating withdrawal symptoms | |
| Jaramillo-Gonzalez | Unlocking Communication: Advancing Brain-Computer Interfaces for ALS Patients in Locked-In and Completely Locked-In States | |
| Guerin | Moving, fast and slow: cognitive control of motor timing examined through the application of the fNIRS technology | |
| Bono | Intensive intervention delivery in autism and early prediction of cognitive outcomes in children using computerised game and wireless EEG in naturalistic setting | |
| WO2025227198A1 (fr) | Plateforme de neuromodulation | |
| WO2025019750A2 (fr) | Systèmes spectroscopiques optiques dynamiques flexibles, dispositifs et procédés de surveillance cardiovasculaire, de tomographie et d'imagerie optique diffuse |